{"nctId":"NCT01560780","briefTitle":"Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis","startDateStruct":{"date":"2013-02-01","type":"ACTUAL"},"conditions":["Coronary Artery Bypass"],"count":84,"armGroups":[{"label":"Arm 1: Prasugrel","type":"EXPERIMENTAL","interventionNames":["Drug: Prasugrel"]},{"label":"Arm 2: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Prasugrel","otherNames":["Effient"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 years or greater\n* Willing and able to give informed consent. The patients must be able to comply with study procedures and follow-up.\n* Undergoing clinically-indicated coronary artery bypass graft surgery\n\nExclusion Criteria:\n\n* Known allergy to aspirin or prasugrel\n* Need for concomitant cardiac procedure, such as valve repair or replacement\n* Increased risk of bleeding, including need for warfarin or dabigatran administration\n* Positive pregnancy test or breast-feeding\n* Coexisting conditions that limit life expectancy to less than 12 months or that could affect a patient's compliance with the protocol\n* Serum creatinine \\> 2.5 mg/dL\n* Severe peripheral arterial disease limiting vascular access\n* Prior stroke or transient ischemic attack\n* Weight \\<60 kg or age \\>75 years\n* Multiple distal SVG anastomoses\n* Postoperative complications prolonging hospitalization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging","description":"Number of patients with intragraft thrombus seen at 12 month follow-up by optical coherence tomography in imaged saphenous vein graft","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Severe Bleeding Using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Criteria","description":"Number of patients with major bleeding defined by the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries criteria.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Angiographic Saphenous Vein Graft Failure","description":"Number of patients with angiographic saphenous vein graft failure (defined as =75% SVG diameter stenosis in at least one saphenous vein graft)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography","description":"Total target saphenous vein graft atheroma volume (mm3) as assessed by Intravascular ultrasound imaging in imaged saphenous vein grafts.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349","spread":"189"},{"groupId":"OG001","value":"358","spread":"175"}]}]}]},{"type":"SECONDARY","title":"Saphenous Vein Graft Lipid Core Burden Index, as Assessed at Near-infrared Intracoronary Spectroscopy","description":"Lipid core burden as measured by Lipid Core Burden Index on near infrared intracoronary spectroscopy imaging of saphenous vein graft. Lipid Core Burden Index is defined as the fraction of pixels within the scanned region with a probability \\>0.60 that a lipid core plaque is present (calculated by an algorithm developed to identify the NIRS signals associated with the molecular structure of lipids), multiplied by 1000 using EchoPlaque software (INDEC Medical Systems; Los Altos, CA) . Thus, the lipid core burden index (LCBI) is a quantitative summary metric of the probability of the presence of lipid within the scanned region, with a range of 0-1000, with higher indices indicating a higher proportion of pixels with a \\>0.6 probability of lipid being present in the pullback of the catheter along the length of the entire vessel.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"9.3"},{"groupId":"OG001","value":"7.4","spread":"15.5"}]}]}]},{"type":"SECONDARY","title":"Major Adverse Cardiac Events, Defined as the Composite of Death, Acute Coronary Syndrome, or Coronary Revascularization) During Follow-up","description":"Number of patients with the composite outcome of death, acute coronary syndrome, or coronary revascularization.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Normalized Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography","description":"On IVUS images, atheroma volume was defined as the sum of the cross-sectional areas between the leading edges of the lumen and external elastic membrane. Total Target SVG atheroma volume was calculated as:\n\n∑(EEM area - Lumen area).\n\nNormalized atheroma volume represents the atheroma volume corrected for pullback length, and this parameter was calculated as:\n\n∑(EEM area - Lumen area)/number of frames in pullback","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.093","spread":"0.045"},{"groupId":"OG001","value":"0.079","spread":"0.035"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":42},"commonTop":[]}}}